DRG Market Assessment reports

MARKET OUTLOOK The ulcerative colitis (UC) market is expected to grow steadily over the next decade. The anticipated entry of first-in-UC oral therapies for the moderate to severe population,…

Market Outlook Pfizer’s Xeljanz is the fist-in-class Jak inhibitor approved for ulcerative colitis (UC) in the United States, and the first targeted oral therapy to launch for the moderate to…

MARKET OUTLOOK Research on the human microbiome is beginning to mature, with microbiome-based therapies reaching the clinical trial phase of development for many disease areas. Significant…

The primary goal of ulcerative colitis (UC) treatment is to induce and maintain remission with few to no clinical symptoms remaining. Conventional therapies (5-ASAs, corticosteroids) are typically…

MARKET OUTLOOK QUESTIONS ANSWERED What are the treatment drivers and goals for [[indication]]? What drug attributes are key influencers, which have limited impact, and which are hidden…

Ulcerative colitis (UC) patients, particularly those with more mild disease activity, will be prescribed a conventional therapy (e.g., 5-ASAs) as first-line treatment; there are multiple generics…

The primary goal of ulcerative colitis (UC) treatment is to induce and maintain remission with few to no clinical symptoms remaining. Conventional therapies (e.g., 5-ASAs, corticosteroids) are…

MARKET OUTLOOK The U.S. ulcerative colitis (UC) and Crohn’s disease (CD) markets include the predominantly entrenched TNF-α inhibitors (e.g., Janssen/Merck’s Remicade, AbbVie/Eisai’s…

The primary goals of pharmacotherapy in UC are to induce remission during acute flares and to maintain long-term corticosteroid-free remission, once remission is achieved. UC treatment regimens are…

MARKET OUTLOOK The ulcerative colitis (UC) market is expected to grow steadily over the next decade. The anticipated entry of first-in-UC oral therapies for the moderate to severe population,…

MARKET OUTLOOK The primary goal of UC treatment is to induce and maintain remission with little to no clinical symptoms remaining. Conventional therapies (5-ASAs, corticosteroids) are typically…

Ulcerative colitis (UC) affects approximately 1.75 million people across the major markets. Aminosalicylates and corticosteroids are routinely prescribed for mild and moderate patients; however,…